Navigation Links
Lpath CEO, Scott Pancoast, to Present Live Online at RetailInvestorConferences.com on June 2 at 1 PM EDT
Date:5/26/2011

NEW YORK, May 26, 2011 /PRNewswire/ -- Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, will present on RetailInvestorConferences.com on June 2, 2011 at 1:00 PM EDT.

Lpath's president and CEO, Scott Pancoast, will discuss the company's progress, including status updates on the PEDigree and Nexus clinical trials, where the company's ocular drug candidate, iSONEP™, is being investigated in human proof-of-concept studies.

To access, follow this link: www.retailinvestorconferences.com and then click on: "Register/Watch Event Now!" Attendees are advised to pre-register and receive event updates.

This will be a live, interactive online event where investors are invited to ask the company questions in real-time in the virtual "presentation hall." After the presentation investors are invited to ask questions and download shareholder materials from the company's "virtual booth." A replay of the event will be available for 90 days.

Lpath entered into an agreement with Pfizer in late 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP for ocular indications. Pfizer and Lpath are collaborating closely on the two iSONEP clinical trials.

Pfizer also has a right of first refusal, which expires in late 2013, for Lpath's cancer drug candidate, ASONEP™. Lpath is planning to further investigate ASONEP in a Phase 2 trial involving renal cell carcinoma patients and perhaps in a second trial involving patients with prostate cancer or neuroblastoma.

About Lpath

San Diego-based Lpath, a therapeutic antibody company, is the category leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeuti
'/>"/>

SOURCE Lpath, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Technest Holdings, Inc. to Acquire AccelPath, LLC; Issue Contingent Value Rights to Common Stockholders; and Issue Shares of Its Series E 5% Convertible Preferred Stock
4. Lpath, Inc. CEO to Present Live, Online at RetailInvestorConferences.com on May 5th
5. Lpath, Inc. CEO Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Ancestry.com DNA Testing Reveals Roots Authors Scottish Ancestry
7. Scottsdale Facility to Be First in U.S. to Showcase True REST Technology
8. Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine
9. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
10. Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
11. Hill-Rom Appoints Scott Jeffers as Senior Vice President, Global Supply Chain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... March 2, 2015 Following announcements from ... transactions, Array BioPharma Inc. (NASDAQ:  ARRY) today announced ... definitive agreements with Novartis.  Along with global ownership ... payment of $85 million from Novartis. ... the close of the Novartis-GSK transaction, Array now ...
(Date:3/2/2015)... NEW YORK , March 2, 2015  Delcath ... pharmaceutical and medical device company focused on oncology with ... liver cancers, announces that Company management will participate in ... held from March 8-11, 2015 at the Ritz Carlton ... Jennifer Simpson , PhD, MSN, CRNP, Delcath,s ...
(Date:3/2/2015)... According to statistics released by the American Society of Plastic ... such as the JUVEDERM ® family of fillers continues ... 2013 to 2014, HA filler treatments increased by 8 percent. ... shows U.S. unit sales of HA dermal fillers were up ... findings are consistent with what I see every day in ...
Breaking Medicine Technology:Array Announces Completion Of Binimetinib And Encorafenib Transactions 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 3Array Announces Completion Of Binimetinib And Encorafenib Transactions 4Array Announces Completion Of Binimetinib And Encorafenib Transactions 5Delcath To Present At The 27th Annual Roth Conference 2Delcath To Present At The 27th Annual Roth Conference 3Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 2Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 3Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 4Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 5Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 6Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 7
... Corporation, a leading developer of whole blood analyzers, today ... CBGM, LLC, has completed the acquisition of certain assets ... , Nova Biomedical is the sole manufacturer, ... (CBGM) subsidiary has become the exclusive distributor, of the ...
... Oct. 7 DATATRAK International, Inc. (OTCQX: DATA), a technology ... clinical trials industry, today announced the signing of a new ... use of a thoracic stent graft in aneurysm repair. ... use of minimally invasive surgical techniques for thoracic aortic aneurysms. ...
Cached Medicine Technology:Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medical's Subsidiary, Sanvita, Inc. 2DATATRAK Signs 6 Year Study with New Device Client 2DATATRAK Signs 6 Year Study with New Device Client 3
(Date:3/2/2015)... 02, 2015 After a rigorous evaluation ... service, pricing and long-term strategy, Blood Centers of America ... choice for member centers’ testing needs. , BCA, which ... more than 30 percent of the U.S. blood supply, ... “BCA is committed to drive cost savings to members,” ...
(Date:3/2/2015)... York, New York (PRWEB) March 02, 2015 ... Creative Recovery at Recovery Unplugged™—will be delivering a ... A Singer/Songwriter's Perspective on the Art of Healing ... Addiction Disorders (NCAD) and Behavioral Healthcare Executive Summit ... his name, Mr. Supa’s songs have been recorded ...
(Date:3/2/2015)... the last five years the ultrasound market has witnessed ... geographic presence and achieve economies of scale. The global ... 2019 at CAGR of 5.1% from 2014 to 2019 ... a major part of Europe are mature markets for ... China and India, Latin America and the Middle East ...
(Date:3/2/2015)... The minimally invasive surgical instruments ... of 6.1% to reach $14,133.0 million by 2019 ... such as advantages of minimally invasive surgeries over ... minimally invasive surgeries and increasing number of surgical ... global minimally invasive surgical instruments market. , For ...
(Date:3/2/2015)... 02, 2015 LegitScript, LLC, ... certification programs, including those for Internet pharmacy ... safety and classification, has launched a certification ... The new program, called iCareRx , ... regarding the identity of the owner/operator of ...
Breaking Medicine News(10 mins):Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 3Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2
... announced the discovery of another gene responsible for late-onset ... the disease (occurring in around 90 percent of patients) ... Boston University, the University of Toronto, and Columbia University ... in Nature Genetics. ,The reasearchers spent ...
... oral chemotherapy in US cancer centres need to be improved, ... ,Common malignancies can be treated with oral chemotherapy – a ... ,Researchers from Boston set out to analyse ... the provision of oral chemotherapy. Forty-two centres took part in ...
... research team works on understanding the heart's natural ... Cardiac Electrophysiology Lab, //she is a faculty member ... subtle rhythms, pulses and patterns of the human ... for millennia, yet the heart's deepest secrets remain ...
... rest on the couch to recover before returning to sports, ... at least not yet. // ,One Ohio State University ... devices for the heart will be put to use temporarily ... Right now, such heart pumps, known commonly as ventricular assist ...
... exposure may differ across Australia, a senior cancer researcher has ... for the production of vitamin D, which is necessary for ... prevention of several cancers. ,Australians are becoming ... out of the sun to avoid skin cancer and getting ...
... Kennedy Center for Research on Human Development has observed ... behavioral //and neurological problems in the child. ,In ... Stanwood, Ph.D., and Pat Levitt, Ph.D., have elaborated about ... which caused a prolonged displacement of dopamine receptors in ...
Cached Medicine News:Health News:New Gene to Help in Understanding Alzheimer’s Diseas 2Health News:Secrets of the Heart's Signals 2Health News:Pumps Someday May Allow Patients to Recover Their Own Hearts 2Health News:Pumps Someday May Allow Patients to Recover Their Own Hearts 3Health News:Safe Sun Exposure a Burning Issue 2Health News:Cocaine During Pregnancy can Cause Behavioral and Neurological Problems in the Child 2Health News:Cocaine During Pregnancy can Cause Behavioral and Neurological Problems in the Child 3
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTN/1Q-CAB chairs are recommended for the ... room, static control, health care and ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
Medicine Products: